Resultados da pesquisa - Paul B. Chapman

Refinar resultados
  1. 1
    The History and Future of Chemotherapy for Melanoma

    The History and Future of Chemotherapy for Melanoma Por Arvin Yang, Paul B. Chapman

    Publicado em 2009
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    The Role of Neoadjuvant Trials in Drug Development for Solid Tumors

    The Role of Neoadjuvant Trials in Drug Development for Solid Tumors Por Samuel A. Funt, Paul B. Chapman

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged

    Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged Por Paul B. Chapman, David B. Solit, Neal Rosen

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Vemurafenib Sensitivity Skin Reaction after Ipilimumab

    Vemurafenib Sensitivity Skin Reaction after Ipilimumab Por James J. Harding, Melissa Pulitzer, Paul B. Chapman

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Carta
    Adic. favoritos
    Na minha lista:
  5. 5
    Peripheral Neuropathy Associated With Ipilimumab

    Peripheral Neuropathy Associated With Ipilimumab Por Iyavut Thaipisuttikul, Paul B. Chapman, Edward K. Avila

    Publicado em 2015
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy

    Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy Por Paul B. Chapman, Sandra P. D’Angelo, Jedd D. Wolchok

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Carta
    Adic. favoritos
    Na minha lista:
  7. 7
    Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells

    Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells Por Dianna Wu, Neil H. Segal, Stéphane Sidobre, Mitchell Kronenberg, Paul B. Chapman

    Publicado em 2003
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines

    Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines Por Emanuela Romano, Michael Scordo, Stephen W. Dusza, Daniel G. Coit, Paul B. Chapman

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Opportunistic infections in patients treated with immunotherapy for cancer

    Opportunistic infections in patients treated with immunotherapy for cancer Por Chrisann Kyi, Matthew D. Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Variates of Survival in Metastatic Uveal Melanoma

    Variates of Survival in Metastatic Uveal Melanoma Por Petra Rietschel, Katherine S. Panageas, Christine Hanlon, Ami B. Patel, David H. Abramson, Paul B. Chapman

    Publicado em 2005
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

    Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) Por Yevgeniy Balagula, Katherine Barth Huston, Klaus J. Busam, Mario E. Lacouture, Paul B. Chapman, Patricia L. Myskowski

    Publicado em 2010
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Osteonecrosis of the jaw a new complication related to Ipilimumab

    Osteonecrosis of the jaw a new complication related to Ipilimumab Por Adepitan A. Owosho, Michael Scordo, Sue S. Yom, Joseph Randazzo, Paul B. Chapman, Joseph M. Huryn, Cherry L. Estilo

    Publicado em 2015
    Obter o texto integral
    Carta
    Adic. favoritos
    Na minha lista:
  13. 13
    Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma

    Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma Por Mrinali Patel, Elizabeth Smyth, Paul B. Chapman, Jedd D. Wolchok, Gary K. Schwartz, David H. Abramson, Richard D. Carvajal

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis

    Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis Por Matthew N. Sirott, Dean F. Bajorin, George Y. Wong, Tao Yue, Paul B. Chapman, Mary Agnes Templeton, Alan N. Houghton

    Publicado em 1993
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients

    Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients Por Ann Y. Lee, Nicolás Droppelmann, Katherine S. Panageas, Qin Zhou, Charlotte E. Ariyan, Mary S. Brady, Paul B. Chapman, Daniel G. Coit

    Publicado em 2016
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Immune Checkpoint Inhibitor-Associated Optic Neuritis

    Immune Checkpoint Inhibitor-Associated Optic Neuritis Por Jasmine H. Francis, Korey Jaben, Bianca Santomasso, Julia Canestraro, David H. Abramson, Paul B. Chapman, Meghan Berkenstock, Mary E. Aronow

    Publicado em 2020
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Dual MEK/AKT inhibition with trametinib and <scp>GSK</scp>2141795 does not yield clinical benefit in metastatic <scp>NRAS</scp>‐mutant and wild‐type melanoma

    Dual MEK/AKT inhibition with trametinib and <scp>GSK</scp>2141795 does not yield clinical benefit in metastatic <scp>NRAS</scp>‐mutant and wild‐type melanoma Por Alain P. Algazi, Rosaura Esteve‐Puig, Adi Nosrati, Brian Hinds, Adele Hobbs‐Muthukumar, Prachi Nandoskar, Susana Ortiz‐Urda, Paul B. Chapman, Adil Daud

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies

    Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies Por Parisa Momtaz, Elena Pentsova, Omar Abdel‐Wahab, Eli L. Diamond, David M. Hyman, Taha Merghoub, Daoqi You, Billel Gasmi, Agnès Viale, Paul B. Chapman

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

    Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma Por Alexander N. Shoushtari, Claire F. Friedman, Pedram Navid-Azarbaijani, Michael A. Postow, Margaret K. Callahan, Parisa Momtaz, Katherine S. Panageas, Jedd D. Wolchok, Paul B. Chapman

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside.

    Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. Por Karl Welte, Glenn T. Miller, Paul B. Chapman, H Yuasa, Edward J. Natoli, Jolanta E. Kunicka, Carlos Cordón-Cardo, Christoph Bührer, Lloyd J. Old, Alan N. Houghton

    Publicado em 1987
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: